Background-The basis for the unique effectiveness of long-term amiodarone treatment on cardiac arrhythmias is incompletely understood. The present study investigated the pharmacogenomic profile of amiodarone on genes encoding ion-channel subunits. Methods and Results-Adult male mice were treated for 6 weeks with vehicle or oral amiodarone at 30, 90, or 180 mg · kg Ϫ1 · d
A miodarone, a widely used antiarrhythmic drug, has remarkable efficacy for the treatment of ventricular tachyarrhythmias and atrial fibrillation. However, the basis for its effectiveness is still poorly understood. The pharmacologic profile of this drug is complex, and much remains to be clarified about both short-and long-term actions. Amiodarone has been referred to as a class III antiarrhythmic agent, 1 but it also possesses electrophysiologic characteristics of class I and IV agents and minor class II effects. 2 The drug is also known to modify thyroid function extensively because of its iodinated nature. 3 The question arose as to whether the long-term effects of amiodarone might stem from its molecular interaction with thyroid hormone receptors or other mechanisms. In particular, it has been hypothesized that the effects of amiodarone could depend on modulation of transcript expression in addition to its direct effect on cell membrane channels. 4 Genomic techniques now bring gene expression studies to a genome scale, allowing investigators to examine simultaneous changes in the expression of the complete gene repertoire. We have developed a specific cDNA microarray (IonChip) containing probes for virtually all known mouse and human ion-channel genes (␣-and ␤-subunits). 5 With this new tool, our previous investigation explored ion-channel remodeling as produced by altered thyroid status in the mouse heart. 5 We now evaluate the effects of long-term amiodarone treatment on global ion-channel expression. Our data show that long-term amiodarone treatment dose-dependently remodels ion-channel expression. Remodeling, which includes downexpression of K ϩ channel genes and of genes involved in conduction, coincides with the dose-dependent effects of amiodarone on mouse cardiac conduction velocity and repolarization. We propose that in addition to the well-known direct effect of the drug on membrane proteins, part of the action of amiodarone on the heart is related to its pharmacogenomic profile.
Methods
An expanded Methods section containing details for microarray, relative quantitative reverse transcription-polymerase chain reaction (RT-PCR), and functional studies and statistical analysis is available in the online-only Data Supplement.
Animal experiments were performed in accordance with institutional guidelines for animal use in research. Ten-week-old male C57BL/6 mice (Iffa Credo, l'Arbresle, France) were used. Mice were treated for 6 weeks with 3 doses of amiodarone (a gift from Dr Patrick Gautier, Sanofi-Synthelabo, Montpellier, France): 30, 90, and 180 mg · kg Ϫ1 · d
Ϫ1
. Sham animals received the same food without amiodarone. The study included 54 sham mice and 18 mice in each amiodarone group. IonChip contained 208 probes representing most mouse ion-channel subunits and connexins cloned so far. The complete probe list can be found at http://www.nantes.inserm.fr/u533.
Results

Effects of Long-Term Amiodarone Treatment on Functional Parameters
Plasma and myocardial levels of amiodarone and N-desethylamiodarone (DEA) were measured in sham and treated animals. As illustrated in Figure 1 Figure 1A ). DEA accumulated dose-dependently in cardiac tissue ( Figure 1B) .
As shown in Table 1 , mice treated with amiodarone at 90 and 180 mg · kg Ϫ1 · d Ϫ1 had decreased body and heart weights, although their heart weight-to-body weight ratios were not significantly different from sham. As expected, 6-week amiodarone treatment induced a decrease in plasma triiodothyronine and an increase in reverse triiodothyronine. This effect reached significance for the 90 and 180 but not for the 30 mg · kg Ϫ1 · d Ϫ1 dose groups. Representative ECG recordings from sham and amiodarone-treated mice are illustrated in Figure 2A . As is evident, the 180 mg · kg Ϫ1 · d Ϫ1 dose prolonged the P-wave duration and the RR, PR, QRS, and QT intervals. Average data reported in Table 2 show that the heart rate and conduction velocity (PR and QRS intervals) were significantly affected by the 90 mg · kg Figure 3 represents the percentage variation of a list of control genes in the 180 mg · kg Ϫ1 · d Ϫ1 group versus sham. Downregulation of cardiac thyroid hormone ␣1-receptor (THRA1) mRNA was previously reported in mice 6 and rats. 7 THRA2 and/or THRA3 mRNA was downregulated, whereas THRB was unaffected. Downregulation of phospholipase A2 coincided with its decreased activity under amiodarone treatment. 8 Upregulation of nitric oxide synthase occurred in accordance with its activation by amiodarone in human veins, 9 whereas downregulation of sphingomyelinase (SMPD1) coincided with its decreased activity in mouse pulmonary endothelial cells. 10 CD4, CD8A, interleukin-1, and interleukin-6 were used as negative controls. Figure 4 illustrates the effects of long-term amiodarone treatment on ion-channel expression. For clarity, only transcripts expressed in the mouse heart are shown. Among the differentially expressed ion-channel subunits were genes involved in cardiac conduction, such as sodium channels ␣-and ␤-subunits (SCN4A, SCN5A, and SCN1B) and connexin 43 (GJA1), which were downregulated. Western blot experiments showed that these modifications were correlated with decreased protein amounts of Nav1.5 (SCN5A) and connexin 43 (data not shown). Calcium homeostasis was affected by amiodarone, with downregulation of Cav1.2 channels (CACNA1C) and Cav␤1-and Cav␤2-subunits (CACNB1 and CACNB2). In addition, the type I sodium-calcium exchanger (SLC8A1), type II calsequestrin (CASQ2), and type III calmodulin (CALM3) were downregulated. The voltage-gated potassium channel genes involved in mouse cardiac repolarization, Kv2.1 (KCNB1), Kv1.5 (KCNA5), and Kv4.2 (KCND2), were downregulated, whereas Kv1.4 (KCNA4) and regulatory subunits such as Kv␤1 (KCNAB1), MiRP1 (KCNE2), and MiRP2 (KCNE3) were upregulated. Two-pore potassium channels, including TWIK-1 (KCNK1), and TASK-2 (KNCK5), and the intermediate/smallconductance calcium-activated potassium channel (KCNN2) were upregulated. It should be noted, however, that these latter genes are expressed at a low level in the mouse heart. Inversely, mRNA expression for Kir6.2 (KCNJ11) and SUR2 (ABCC9) forming ATP-sensitive K ϩ channels were downregulated. This was also observed for the two-pore K ϩ channel gene TASK (KCNK3).
We used real-time PCR to confirm differential expression of 18 selected genes and also to explore dose dependence ( Figure 5 ). The results show excellent qualitative correlation between microarray and PCR data. As previously observed, 5 however, comparison of the obtained fold changes with microarray analysis versus real-time PCR revealed larger differences with the latter approach. For example, SCN5A transcripts decreased by Ϸ40% (180 mg · kg Ϫ1 · d Ϫ1 dose) in real-time PCR experiments, whereas changes detected with the microarrays, though significant, were Ϸ20%. Most important, real-time PCR data showed that long-term amiodarone treatment dose-dependently regulated the expression of a large set of ion channels. Interestingly, the 30 mg · kg
dose, which did not affect the surface ECG, produced no effect on ion-channel expression. Finally, genes targeted as nonvariant by microarray analysis, such as GJA5, KCNE1, and KCNQ1, were also nonvariant in real-time PCR analysis.
Functional Correlation With Molecular Data
Whole-cell patch-clamp recordings were conducted in ventricular myocytes isolated from sham and 180 mg · kg
amiodarone-treated hearts. As illustrated in Figure 6A , the amplitude of the transient outward current I to was reduced significantly in the amiodarone-treated group. This was correlated with the observed downregulation of Kv4.2 (KCND2) expression. Similarly, the density of the current remaining at the end of 400-ms pulses, which reflects I K,slow , 11 was also significantly decreased, in accordance with the reduced expression of Kv1.5 (KCNA5) and Kv2.1 (KCNB1). By contrast, the density of the steady-state current remaining at the end of 4-second pulses, I ss , 11 was not modified by long-term amiodarone treatment (2.94Ϯ0.47 vs 2.52Ϯ0.32 pA/pF at ϩ50 mV in sham and amiodarone-treated myocytes, respectively; not illustrated). The amplitude of the inwardly rectifying background K ϩ current I K1 was not affected ( Figure  6B ), which was correlated with the molecular data, because neither Kir2.1 (KCNJ2) nor Kir2.2 (KCNJ12) mRNA was affected in amiodarone-treated mice. Voltage-clamp experiments further revealed that the peak inward sodium current (I Na ) decreased by 33Ϯ6 pA/pF (PϽ0.001) in amiodaronetreated myocytes ( Figure 6C ). These data are also correlated with the reduced expression of SCNA5 mRNA in microarrays. Surprisingly, the L-type calcium current density was unmodified in treated mice (data not shown), contrasting with the 50% reduced expression of CACNA1C in real-time RT-PCR experiments.
Discussion
The present study shows that amiodarone dosedependently remodels cardiac ion-channel expression and 
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that remodeling is correlated with the cardiac electrophysiologic effects of the drug, ie, slowed conduction (decreased SCN5A, SCN4A, and GJA1 expression) and prolonged repolarization (decreased KCND2, KCNB1, and KCNA5 expression). These gene expression modifications impact the corresponding current density and/or protein level. Importantly, the prolongation of cardiac repolarization induced by 180 mg · kg Ϫ1 · d Ϫ1 amiodarone was associated with a complex rearrangement of several repolarizing K ϩ channel genes. These include not only decreased expression of the major K ϩ channels involved in mouse cardiac repolarization but also increased expression of other K ϩ channel subunits (KCNA4, KCNAB1, KCNE2, and KCNE3). We previously observed a comparable rearrangement in the same mouse model under the effects of hypothyroism. 5 To our knowledge, this is the first largescale study showing pharmacogenomic effects of an antiarrhythmic drug, which at least partly account for the control of mouse cardiac electrical function by amiodarone and potentially for its antiarrhythmic action, in addition to the known direct effect of the drug on membrane proteins.
Comparison With Previous Studies
Despite the high doses of amiodarone administered to mice, plasma and myocardial concentrations remained within the therapeutic range observed in patients. 12, 13 One difference with the clinical situation is the low level of DEA plasma and myocardial concentrations, which never exceeded 0.3 time the parent compound, whereas in humans, concentrations of DEA can be as high as 3 times those of amiodarone. This is consistent with previous observations in animal studies 14 -16 and is probably related to species differences in liver metabolism.
In our model, long-term amiodarone treatment induced a dose-dependent bradycardia and a decrease in conduction velocity, in agreement with previous clinical and experimental findings. 17 The small but significant increase in corrected QT at the highest dose of amiodarone is also consistent with the 5% to 18% increase obtained in different animal models treated orally for the same period of time. 18, 19 In humans, the prolongation of repolarization rarely exceeds 10% to 15%, as assessed with surface ECG 20 or monophasic action potential (MAP) recording. 21, 22 Early on, Drvota and coworkers 4 performed in vitro experiments suggesting that the effects of DEA on cardiac electrical activity could depend on gene expression. In their extensive 1997 review, Kodama et al 15 expression of Kv1.5 (KCNA5) in rats treated with amiodarone. Our results show that remodeling affects every gene family represented on our microarrays. As previously mentioned, amiodarone induced a prolongation of ventricular repolarization that can be explained by the decrease in I to and I K,slow current densities. A decrease in I to density without alteration in its voltage dependence has already been described in different models 23, 24 and can be explained partly by the decreased expression of Kv4.2 (KCND2). Similarly, the decreased expressions of Kv2.1 (KCNB1) and to a lesser extent of Kv1.5 (KCNA5) are consistent with the reduction of I K,slow . In the rat, I sus , a current similar to I K,slow , is also decreased by long-term amiodarone, 23 probably because of the decreased expression in Kv1.5 (KCNA5). 15 Finally, a previous study in rabbits has shown that long-term amiodarone administration decreases the I Ks current density without affecting KCNQ1 or KCNE1 mRNA. 25 We observed that Ca 2ϩ channel subunits, including Cav1.2 that forms the pore of the myocardial L-type Ca 2ϩ channel (I Ca,L ), are downregulated in treated mice, consistent with previous binding studies. 26 At the functional level, however, previous results are conflicting, because I Ca,L has been shown to be either decreased or increased 15 by long-term amiodarone administration. In our model, the I Ca,L current density was unaffected by amiodarone. This finding opposes the decreased expression of CACNA1C, suggesting either posttranscriptional or/and translational mechanisms or compensatory adaptation linked to the expression of CACNB1 and CACNB2 regulatory subunits. In fact, we found that the expression of the regulatory subunit was largely altered by amiodarone. Because these regulatory proteins can exert close control of current amplitude, 27 the correlation between changes in gene expression and function may not be straightforward.
Potential Mechanisms for Amiodarone-Induced Ionic Remodeling
The mechanism of the relation between oral amiodarone dose and gene expression is principally unknown. Some genes (ie, SCN5A, GJA1, etc) show progressive remodeling in relation to dose, whereas others (ie, CACNA1C, KCNA4, etc) do not. Different nonexclusive hypotheses can explain ionic remodeling, including (1) the hypothyroidism syndrome induced by amiodarone, (2) a direct effect of amiodarone/DEA on gene promoters, (3) an effect of amiodarone/DEA on transcription factors, and (4) physiologic alterations induced by direct effects of the drug on membrane proteins.
Amiodarone is a diiodinated benzofuran derivative that presents structural similarities to thyroid hormones. 28 Cardiac electrophysiologic changes induced by long-term amiodarone closely resemble those induced by hypothy- roidism (for a review, see Kodama et al 15 ). However, hypothyroidism does not mimic all amiodarone long-term effects. 29, 30 Recently, Bosh et al 30 have shown that hypothyroidism and long-term amiodarone have different effects on guinea pig cardiac K ϩ currents and that their combination prolongs repolarization to a greater extent than either alone. Our study also suggests that amiodaroneinduced ionic remodeling cannot be explained by hypothyroidism alone. Indeed, although some of the variations in transcripts induced by long-term amiodarone treatment are similar to those induced by hypothyroidism in the same mouse model, 5 eg, the decreased expression of KCNA5, KCNB1, or KCND2, the expression of several genes such as GJA1, KCNA4, KCNAB1, and KCNJ11 that are not regulated by thyroid function appear to be regulated by amiodarone. In addition, genes such as CACNA1C, SLC8A1, KCNE1, and KCNQ1 were upregulated by hypothyroidism, whereas others were downregulated (CACNA1C, SLC8A1) or unmodified (KCNE1, KCNQ1) by amiodarone. Finally, nongenomic effects of thyroid hormones are not inhibited by amiodarone. 29, 30 Thus, it is not surprising that long-term amiodarone treatment causes remodeling of ion channels different from those associated with systemic hypothyroidism.
One can also speculate that amiodarone can directly modify gene expression. Amiodarone, or most probably DEA, may interfere with nuclear receptor/coactivator interaction. 31, 32 It reduces basal LDL receptor promoter activity. It also disrupts the interaction between the glucocorticoid receptor interacting protein-1 and the thyroid hormone receptor ␤1.
Alternatively, ionic remodeling could be a long-term consequence of the effects of amiodarone on ionic-channel proteins and could result from an adaptation of the myocytes to a new physiologic steady state. This hypothesis seems least plausible. If true, one would expect, for instance, compensatory overexpression of Na ϩ and Ca 2ϩ channel subunits that are major targets of short-term amiodarone treatment, rather than downexpression, as observed in our model.
Clinical and Physiologic Implications
Our results contribute to understanding of the unique profile of amiodarone in the treatment of arrhythmias and may account for the long-term effects of the drug, which differ from its short-term effects. However, their clinical relevance remains unclear for at least 2 reasons: (1) the choice of species dictated by the availability of extensive genomic information and (2) the absence of primary cardiac pathology with or without arrhythmias. It is therefore essential to investigate whether remodeling is also observed in humans and how it interferes with the remodeling resulting from cardiac pathologies.
